| http://www.w3.org/ns/prov#value | - To learn more about this study, including eligibility criteria, please visit http://clinicaltrials.gov/ct2/show/NCT01695343?term=kb001a&rank=1The FDA's designation of KB001-A as an orphan drug is another milestone for KaloBios as we continue the clinical development work required for potential FDA approval, said David W. Pritchard, KaloBios' President and Chief Executive Officer.
|
